
The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.
Dr. David Pearlstone from John Theurer Cancer Center Discusses Mammogram Deterrents
David Pearlstone, MD, co-division chief, Breast Oncology from John Theurer Cancer Center discusses mammogram deterrent.





